Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2015-03-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00262-015-1679-3PMID 25795132PMCID PMC11029723
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas

  2015cited by this paper
• Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation

  2014cited by this paper
• FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.

  2013cited by this paper
• Pancreatic cancer.

  2013cited by this paper
• Low‐dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer

  2013cited by this paper
• FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?

  2013cited by this paper
• Therapeutic Endoscopic Ultrasonography: Intratumoral Injection for Pancreatic Adenocarcinoma

  2013cited by this paper
• Intraprostatic distribution and long term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer

  2013cited by this paper
• Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

  2013cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

  2012influential reference
• Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness

  2012cited by this paper
• Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models

  2011cited by this paper
• Long‐term follow‐up of patients with resected pancreatic cancer following vaccination against mutant K‐ras

  2011cited by this paper
• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  2011cited by this paper
• Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13

  2011cited by this paper
• Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.

  2011cited by this paper
• Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.

  2011cited by this paper
• Cytotoxic immunotherapy strategies for cancer: Mechanisms and clinical development

  2011cited by this paper
• A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation

  2011cited by this paper
• Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.

  2010cited by this paper
• Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

  2010cited by this paper
• Current status of adjuvant therapy for pancreatic cancer.

  2010cited by this paper
• Pancreatic cancer.

  2010cited by this paper
• 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.

  2010cited by this paper
• Systemic effects of local radiotherapy.

  2009cited by this paper
• Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation

  2008cited by this paper
• Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

  2007cited by this paper
• Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer.

  2006cited by this paper
• In vitro and in vivo enhancement of ganciclovir-mediated bystander cytotoxicity with gemcitabine.

  2005cited by this paper
• Long-term Follow-up of Patients with Malignant Pleural Mesothelioma Receiving High-Dose Adenovirus Herpes Simplex Thymidine Kinase/Ganciclovir Suicide Gene Therapy

  2005cited by this paper
• Patients Undergoing Treatment for Pancreatic Adenocarcinoma Can Mount an Effective Immune Response to Vaccinations

  2005cited by this paper
• Impaired function of circulating dendritic cells in patients with pancreatic cancer.

  2005cited by this paper
• Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir.

  2005cited by this paper
• Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients

  2004cited by this paper
• Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.

  2004cited by this paper
• Cytokines in pancreatic carcinoma

  2004cited by this paper
• Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1

  2002cited by this paper
• Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire.

  2002cited by this paper
• Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up.

  2001cited by this paper
• Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?

  2001cited by this paper
• In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer.

  2001cited by this paper
• Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer.

  2001cited by this paper
• Prostate-Specific Antigen Response and Systemic T Cell Activation After In Situ Gene Therapy in Prostate Cancer Patients Failing Radiotherapy

  2001cited by this paper
• Immune-dependent distant bystander effect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis

  2001cited by this paper
• Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors.

  2000cited by this paper
• Cancer gene therapy with HSV‐tk/GCV system depends on t‐cell‐mediated immune responses and causes apoptotic death of tumor cells In vivo

  1999cited by this paper
• Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo.

  1999cited by this paper
• Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer.

  1999cited by this paper
• Adenovirus‐mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer

  1997cited by this paper
• Pancreatic carcinoma cell killing via adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene.

  1997cited by this paper
• Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect".

  1996cited by this paper
• Adenovirus‐mediated gene therapy of experimental gliomas

  1994cited by this paper
• Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component.

  1994cited by this paper
• Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo.

  1994cited by this paper

• Gene, genetics and genetic medicines in gastroenterology: Current status and its future

  2026cites this paper
• Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy

  2025cites this paper
• Cetuximab-mediated antibody-dependent cell-mediated cytotoxicity enhances anti-tumor efficacy of patient-derived natural killer cells in pancreatic cancer.

  2025cites this paper
• Oncolytic viruses: A novel therapeutic approach for pancreatic cancer

  2025influential citation
• Suicide gene therapy targeting ewing sarcoma via an ewing-specific GGAA promoter

  2025cites this paper
• A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma.

  2025cites this paper
• Smart nanocarriers for enzyme-activated prodrug therapy

  2024cites this paper
• The Current Landscape of Clinical Trials for Immunotherapy in Pancreatic Cancer: A State-of-the-Art Review

  2024cites this paper
• Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer

  2023cites this paper
• Therapeutic potential of gene therapy for gastrointestinal diseases: Advancements and future perspectives

  2023cites this paper
• The clinical terrain of immunotherapies in heterogeneous pancreatic cancer: unravelling challenges and opportunities

  2023cites this paper
• Intrapleural Anticancer Therapy for Malignant Pleural Diseases: Facts or Fiction?

  2023cites this paper
• Oncolytic virotherapy: basic principles, recent advances and future directions

  2023cites this paper
• Review of Safety Data for Adenovirus 5 as a Delivery Vector for Intratumoral Cancer Gene Therapy

  2023cites this paper
• Treatment of Human Pancreatic Cancers Following Local and Systemic Administration of Oncolytic Adenovirus Serotype 35

  2023cites this paper
• Pancreatic Cancer Cell and Gene Biotherapies: Past, Present, and Future

  2022cites this paper
• Role of Adenoviruses in Cancer Therapy

  2022cites this paper
• An Extensive Review on Preclinical and Clinical Trials of Oncolytic Viruses Therapy for Pancreatic Cancer

  2022cites this paper
• Immunotherapy in pancreatic cancer-an emerging role: a narrative review.

  2022cites this paper
• Image-Guided Intratumoral Delivery of Immunotherapeutics in Gastrointestinal Malignancies

  2021cites this paper
• Pancreatic Cancer and Immunotherapy: A Clinical Overview

  2021cites this paper
• Quality of Life Instruments and Trajectories After Pancreatic Cancer Resection

  2021cites this paper
• Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy

  2021cites this paper
• Trends in patient‐reported outcome use in early phase dose‐finding oncology trials – an analysis of ClinicalTrials.gov

  2021cites this paper
• New Nanomaterials and Techniques for Tumor-targeted Systems

  2020cites this paper
• The use of patient reported outcome measures (PROMs) in palliative radiotherapy: a topical review.

  2020cites this paper
• The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database

  2020cites this paper
• The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis

  2020cites this paper
• Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity

  2020cites this paper
• Tumor Therapeutic Modes

  2020cites this paper
• The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer

  2020cites this paper
• Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges

  2019cites this paper
• Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy

  2019cites this paper
• Impact of Immunotherapy after Resection of Pancreatic Cancer.

  2019cites this paper
• Alpha-Herpesvirus Thymidine Kinase Genes Mediate Viral Virulence and Are Potential Therapeutic Targets

  2019cites this paper
• Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy

  2019cites this paper
• Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.

  2018cites this paper
• Advances in oncolytic adenovirus therapy for pancreatic cancer.

  2018cites this paper
• An Antibody Designed to Improve Adoptive NK-Cell Therapy Inhibits Pancreatic Cancer Progression in a Murine Model

  2018cites this paper
• Engineered Thymidine-Active Deoxycytidine Kinase for Bystander Killing of Malignant Cells.

  2018cites this paper
• Gene Therapy for Pancreatic Diseases: Current Status

  2018cites this paper
• Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma

  2018cites this paper
• Immunotherapy and gene therapy as novel treatments for cancer

  2017cites this paper
• Cancer Immunotherapy: Friend or Foe of Mental Health?

  2017cites this paper
• Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes

  2017cites this paper
• Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses.

  2017cites this paper
• Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment

  2016cites this paper
• Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma

  2016cites this paper
• Surgical immune interventions for solid malignancies.

  2016cites this paper
• Enzyme/Prodrug Systems for Cancer Gene Therapy

  2016cites this paper
• Coinhibitory Pathways in Immunotherapy for Cancer.

  2016cites this paper
• Current clinical trials testing the combination of immunotherapy with radiotherapy

  2016cites this paper
• Second pancreatectomy for recurrent pancreatic ductal adenocarcinoma in the remnant pancreas: A pooled analysis.

  2016cites this paper
• Improving the safety of cell therapy with the TK-suicide gene

  2015cites this paper
• Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.

  2015cites this paper